Supernus Pharmaceuticals (SUPN) Projected to Post Quarterly Earnings on Tuesday

Supernus Pharmaceuticals (NASDAQ:SUPN) is expected to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.41 per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Supernus Pharmaceuticals Stock Up 2.0%

Shares of NASDAQ SUPN opened at $50.84 on Tuesday. The business has a 50-day moving average price of $49.80 and a 200 day moving average price of $47.58. The stock has a market cap of $2.92 billion, a PE ratio of -149.53, a price-to-earnings-growth ratio of 0.64 and a beta of 0.71. Supernus Pharmaceuticals has a 52-week low of $29.16 and a 52-week high of $57.65.

Insider Activity at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 710 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the transaction, the vice president directly owned 14,508 shares of the company’s stock, valued at approximately $644,735.52. This represents a 4.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Frank Mottola sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $50.41, for a total value of $1,008,200.00. Following the completion of the sale, the senior vice president owned 15,496 shares in the company, valued at approximately $781,153.36. This trade represents a 56.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 8.80% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in SUPN. Royal Bank of Canada increased its holdings in Supernus Pharmaceuticals by 68.1% in the first quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock valued at $382,000 after buying an additional 4,729 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 35.2% in the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after buying an additional 22,182 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Supernus Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock valued at $978,000 after buying an additional 1,297 shares in the last quarter. Millennium Management LLC raised its stake in shares of Supernus Pharmaceuticals by 370.5% during the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after buying an additional 112,886 shares during the last quarter. Finally, Empowered Funds LLC boosted its position in shares of Supernus Pharmaceuticals by 16.0% in the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after buying an additional 6,619 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on SUPN shares. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Bank of America started coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They set a “buy” rating and a $65.00 price objective on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 31st. Finally, Stifel Nicolaus raised their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a report on Friday, December 19th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Supernus Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $61.60.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.